Aduro Biotech Inc. (ADRO) Insider Thomas W. Dubensky Sells 25,000 Shares
Aduro Biotech Inc. (NASDAQ:ADRO) insider Thomas W. Dubensky sold 25,000 shares of the firm’s stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $12.68, for a total value of $317,000.00. Following the transaction, the insider now owns 55,424 shares in the company, valued at $702,776.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Aduro Biotech Inc. (NASDAQ:ADRO) opened at 13.64 on Thursday. The firm’s market capitalization is $883.24 million. The stock’s 50 day moving average price is $14.13 and its 200-day moving average price is $13.11. Aduro Biotech Inc. has a one year low of $7.26 and a one year high of $34.95.
Aduro Biotech (NASDAQ:ADRO) last released its earnings results on Wednesday, August 3rd. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.21. The company earned $39 million during the quarter, compared to the consensus estimate of $25.24 million. Aduro Biotech had a negative return on equity of 9.23% and a negative net margin of 23.69%. The business’s revenue was up 306.3% on a year-over-year basis. On average, equities research analysts anticipate that Aduro Biotech Inc. will post ($1.39) earnings per share for the current fiscal year.
Several equities analysts recently issued reports on the company. Canaccord Genuity restated a “buy” rating and set a $30.00 price objective on shares of Aduro Biotech in a research note on Friday, August 5th. Zacks Investment Research lowered Aduro Biotech from a “hold” rating to a “sell” rating in a research report on Monday, July 18th. Finally, Roth Capital reaffirmed a “buy” rating and issued a $22.00 target price on shares of Aduro Biotech in a research report on Monday, July 11th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Aduro Biotech has a consensus rating of “Hold” and a consensus target price of $22.00.
Several large investors have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. increased its stake in Aduro Biotech by 198.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 65,571 shares of the company’s stock worth $742,000 after buying an additional 43,636 shares during the last quarter. American Century Companies Inc. purchased a new stake in Aduro Biotech during the second quarter worth $1,265,000. Metropolitan Life Insurance Co. NY purchased a new stake in Aduro Biotech during the second quarter worth $312,000. QVT Financial LP purchased a new stake in Aduro Biotech during the second quarter worth $2,171,000. Finally, AQR Capital Management LLC purchased a new stake in Aduro Biotech during the second quarter worth $821,000. Institutional investors own 29.76% of the company’s stock.
Aduro Biotech Company Profile
Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.